SIGFOX
6.1.2022 11:02:07 CET | Business Wire | Press release
Sigfox, a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer, today announces its partnership with HT Micron, a Brazilian expert in advanced semiconductor solutions, and Nowi, a semiconductor company that specializes in the development of energy harvesting power management technology, to explore and unlock the benefits of integrating energy harvesting into Sigfox devices.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220106005406/en/
This collaboration marks the first step for Sigfox towards a commercial development of energy harvesting modules to equip IoT devices and contribute to more sustainability in IoT. Key use cases are applications in Smart metering, industrial sensoring, asset tracking and air quality monitoring.
During the research phase, HT Micron has worked on creating the innovative semiconductor solution to be integrated with Nowi’s Energy Harvesting PMIC (Power Management Integrated Circuit) designed especially for low power IoT devices. Equipped on Sigfox devices and powered by the 0G technology, this solution will help reduce battery consumption and offer longer autonomy while reducing the total cost of ownership.
Nowi PMIC is designed to efficiently extract power from ambient energy sources like light and vibration to charge a variety of energy storage elements such as a rechargeable battery or a capacitor. It is best suited for most low power applications like distributed IoT sensors and TV remote controls for example.
“The low power consumption of Sigfox solutions is particularly well suited to being powered by ambient energy harvesting. As many Sigfox-based applications require intermittent communication intervals, this allows for trickle charging a storage element with energy harvesting in between transmissions ,” explains Chris Juliano, CCO at Nowi .
Sigfox and HT Micron have been working together for several years already and HT Micron was identified as a strategic partner for this project as they have the expertise to create innovative modules and they consider energy harvesting essential for IoT mass adoption with sustainability.
“We are glad to take this next step with Sigfox and explore energy harvesting solutions as a new way to create added value to our end customers and help them improve their environmental impact ,” says Edelweis Ritt, CIO at HT Micron .
“This collaboration with Nowi and HT Micron is another proof point towards our ambition to create IoT solutions that will help our clients preserve the environment by greatly reducing their energy consumption. We are looking forward to the development of this new kind of devices and to the positive impact they will generate ” says Benjamin Jooris, Client & Ecosystem Success Director at Sigfox.
The first step of this project is a development kit integrating Nowi’s PMIC solution with HT Micron’s Sigfox system-in-package, to be used for testing purposes by R&D and product development teams. First information will be presented at CES 2022 (5-7 January in Las Vegas) at Nowi’s booth (#51733) to gather customer and developers’ feedback. Customers can register to receive the development kit. Next, Sigfox, Nowi and HT Micron will create a mass production module that can be used by any type of device maker.
This announcement comes as part of strengthening Sigfox's strategy to help reduce the human impact on the environment with IoT, and it will be soon followed by other solutions based on energy harvesting as new projects are already in discussion.
****
About Sigfox
Sigfox is a world’s leading IoT (Internet of Things) communication service provider and 0G network pioneer. Sigfox offers a unique combination of ultra-low cost and ultra-low power solutions enabled by a single global network, owned and operated by 75 Sigfox Operators, enabling businesses to gain visibility and track their assets worldwide. With more than 19 million connected devices and 75 million messages sent a day, Sigfox helps its customers to extract data at the lowest cost of production and accelerate their digital transformation in key areas such as asset tracking and monitoring.
ISO 9001 certified and supported by a strong partner ecosystem, Sigfox was founded in 2010 and is headquartered in Labège, France, with offices in Boston, Dallas, Dubai, Madrid, Paris, Sao Paulo, Singapore, and Tokyo.
About Nowi
Nowi is a semiconductor company founded in 2016, based in Delft, the Netherlands, with regional offices in the US and in Shanghai.
Nowi has developed energy harvesting power management ICs that combine top harvesting performance with the world’s smallest assembly footprint and lowest BOM cost. Thereby it simplifies the design process and lowers the threshold for any company to develop ‘Plug & Forget’ products.
About HT Micron
HT Micron provides advanced semiconductor solutions. The portfolio includes memories for computers, cell phones and smart TVs, as well as System-in-Package connectivity solutions for the Internet of Things. HT Micron is a Brazilian company, having as the main shareholder the South Korean group HANA Micron, and is based in the city of São Leopoldo, RS, in South Brazil.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220106005406/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
